SynthesisMedicine2017
Role of CDH13 promoter methylation in the carcinogenesis, progression, and prognosis of colorectal cancer: A systematic meta-analysis under PRISMA guidelines.
Synthesis in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Pooled it
- Environmental Xenobiotics and Epigenetic Modifications: Implications for Human Health and Disease.Journal of xenobiotics · 2025Review
- A Haplotype GWAS in Syndromic Familial Colorectal Cancer.International journal of molecular sciences · 2025Article
- Caveolin-1 knockout mitigates breast cancer metastasis to the lungs via integrin α3 dysregulation in 4T1-induced syngeneic breast cancer model.Cancer gene therapy · 2024Article
- High-Resolution Melting (HRM) analysis of DNA methylation using semiconductor chip-based digital PCR.Genes & genomics · 2024Article
- The CpG island methylator phenotype increases the risk of high-grade squamous intraepithelial lesions and cervical cancer.Clinical epigenetics · 2022Article
- The Interaction Between Epigenetic Changes, EMT, and Exosomes in Predicting Metastasis of Colorectal Cancers (CRC).Frontiers in oncology · 2022Review
- microRNA-377-3p downregulates the oncosuppressor T-cadherin in colorectal adenocarcinoma cells.Cell biology international · 2021Article
- Interactive association between dietary fat and sex on CDH13 cg02263260 methylation.BMC medical genomics · 2021Article
- Cadherins down-regulation: towards a better understanding of their relevance in colorectal cancer.Histology and histopathology · 2020Review
- DNA polymerase beta modulates cancer progression via enhancing CDH13 expression by promoter demethylation.Oncogene · 2020Article
- Genome-Wide DNA Methylation Analysis of Mammary Gland Tissues From Chinese Holstein Cows WithFrontiers in genetics · 2020Article
- Adiponectin as Link Factor between Adipose Tissue and Cancer.International journal of molecular sciences · 2019Review
- The Relevance of Gender in Tumor-Influencing Epigenetic Traits.Epigenomes · 2019Review
- Adiponectin Receptors and Pro-inflammatory Cytokines Are Modulated in Common Variable Immunodeficiency Patients: Correlation With Ig Replacement Therapy.Frontiers in immunology · 2019Article
- Cadherin Signaling in Cancer: Its Functions and Role as a Therapeutic Target.Frontiers in oncology · 2019Review
- Genetic variation inOncotarget · 2018Article
- Role ofOncoTargets and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundH-cadherin (CDH13) is commonly downregulated through promoter methylation in various cancers. However, the role of CDH13 promoter methylation status in patients with colorectal cancer (CRC) remains to be clarified.
methodsEligible articles were identified from online electronic database based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement criteria. The pooled odds ratio (OR) and the corresponding 95% confidence interval (95% CI) were calculated and analyzed.
resultsEventually, a total of nine studies were included in this meta-analysis, including 488 CRC, 298 adjacent, 144 normal, 68 premalignant tissues. The results demonstrated that CDH13 promoter methylation was notably higher in CRC than in normal, adjacent, and premalignant tissues (cancer tissues vs normal tissues: OR = 16.94, P < 0.001; cancer tissues vs adjacent tissues: OR = 20.06, P < 0.001; cancer tissues vs premalignant tissues: OR = 2.23, P = 0.038). CDH13 promoter methylation had a significantly increased risk for poorly differentiated CRC (OR = 4.07, P = 0.001). CDH13 promoter methylation was not associated with sex status, tumor stage, and lymph node status (all P > 0.05). One study with 85 CRC patients reported that CDH13 promoter methylation was correlated with poor prognosis in overall survival (OS).
conclusionsCDH13 promoter methylation may play an important role in the initiation and progression of CRC, and may be correlated with OS of patients with CRC. Additional studies with large sample sizes are needed to further confirm our findings in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.